<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215237</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF2018LSK-91</org_study_id>
    <nct_id>NCT04215237</nct_id>
  </id_info>
  <brief_title>How Atorvastatin Affects the Gut Flora and Metabolomics?</brief_title>
  <official_title>A Clinical Observational Trail on Atorvastatin Regulates Intestinal Flora and Metabolomics.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies suggest that gut microbiome, the microbial community in the intestine, may
      directly and indirectly influence the progression of atherosclerosis. The imbalance of gut
      microbiome may directly promote the formation of atherosclerotic plaques by promoting the
      inflammatory reaction and oxidative stress affecting vascular endothelial function and
      increasing platelet activity. Meanwhile, it can indirectly increase the risk of
      atherosclerosis by enhance insulin resistance, reducing the production of bile acids and
      raising serum LDL-C and angiotensin levels. As shown in these researches, gut microbiome,
      acting as a bridge between metabolism, energy and inflammatory responses, may play an
      important role in cardiovascular diseases, and we believe that the interaction between
      microbiome and host should be considered in the ASCVD study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of flora</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Atorvastatin regulates intestinal flora</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20 Mg Oral Tablet</intervention_name>
    <description>Atorvastatin 20mg oral once a day</description>
    <arm_group_label>Atorvastatin regulates intestinal flora</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80 years;

          -  Statin indications such as lipid metabolism disorders, diabetes, elevated CRP,
             atherosclerosis; stratification according to ASCVD risk; indications for statin
             treatment

          -  Not using statins and other lipid-lowering drugs for at least 6 months before
             enrollment;

          -  Agree to receive research treatment plan;

          -  Voluntarily sign the informed consent.

        Exclusion Criteria:

          -  People with active gastrointestinal bleeding or have a clear history of
             gastrointestinal ulcers or bleeding in the past 2 years;

          -  Severe renal insufficiency (eGFR &lt;30ml / min / 1.73m2);

          -  Active hepatitis, liver cirrhosis, or ALT increase more than 3 times;

          -  Those with severe hypertension (&gt; 180 / 110mmHg) and currently have no control;

          -  Hemoglobin &lt;100g / L;

          -  Platelet count &lt;100 Ã— 109 cells / L;

          -  Suffering from a known serious progressive disease (such as a malignant tumor) or a
             disease that causes the patient to fail extremely, the estimated survival time is &lt;12
             months;

          -  pregnant or intending to become pregnant;

          -  Any situation that may interfere with the research process, such as dementia,
             paralysis, alcoholism, etc .;

          -  Expected to undergo surgery within 1 year;

          -  Patients participating in other ongoing clinical studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zuyi Yuan, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yue Wu, Professor</last_name>
    <phone>18092826334</phone>
    <email>imyuewu@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiang Hao</last_name>
    <phone>15877383294</phone>
    <email>drhaoxiang@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Hao</last_name>
      <phone>+86 15877383294</phone>
      <email>drhaoxiang@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue Wu, Professor</last_name>
      <phone>0086-029-8532-3664</phone>
      <email>imyuewu@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

